12 years of historical data (2013–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CytomX Therapeutics, Inc. trades at 14.1x earnings, 421% above its 5-year average of 2.7x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 40%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $430M | $87M | $114M | $105M | $278M | $302M | $377M | $629M | $785M | $398M | $741M |
| Enterprise Value | $401M | $59M | $111M | $-70409250 | $94M | $135M | $216M | $382M | $607M | $294M | $681M |
| P/E Ratio → | 14.13 | 2.71 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.11 | 0.63 | 1.13 | 1.98 | 7.44 | 4.42 | 6.55 | 10.57 | 10.95 | 26.47 | 96.05 |
| P/B Ratio | — | — | — | — | — | — | 7.37 | 4.81 | 11.23 | 5.07 | 5.88 |
| P/FCF | — | — | — | — | — | 102.46 | — | — | 4.65 | — | — |
| P/OCF | — | — | — | — | — | 57.47 | — | — | 4.61 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
CytomX Therapeutics, Inc.'s enterprise value stands at 15.0x EBITDA, 585% above its 5-year average of 2.2x. The Healthcare sector median is 13.8x, placing the stock at a 8% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.42 | 1.10 | -1.32 | 2.52 | 1.98 | 3.76 | 6.41 | 8.48 | 19.52 | 88.30 |
| EV / EBITDA | 15.00 | 2.19 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 16.06 | 2.35 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 45.85 | — | — | 3.60 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
CytomX Therapeutics, Inc. earns an operating margin of 18.1%. Operating margins have expanded from -190.6% to 18.1% over the past 3 years, signaling improving operational efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | 18.1% | 18.1% | -6.4% | -190.6% | -311.0% | -117.7% | -192.9% | -130.9% | -64.6% | -396.1% | -430.5% |
| Net Profit Margin | 23.1% | 23.1% | -0.6% | -186.8% | -310.5% | -94.7% | -177.8% | -142.2% | -60.2% | -391.5% | -458.7% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -299.1% | -112.4% | -84.3% | -58.1% | -57.6% | -148.9% |
| ROA | 19.8% | 19.8% | -0.2% | -33.1% | -33.2% | -18.5% | -25.6% | -19.8% | -14.4% | -29.7% | -26.2% |
| ROIC | — | — | — | — | — | — | — | — | — | -223.0% | -37.6% |
| ROCE | 62.0% | 62.0% | -8.4% | -54.8% | -42.0% | -29.5% | -36.1% | -22.4% | -18.5% | -34.6% | -27.3% |
Solvency and debt-coverage ratios — lower is generally safer
CytomX Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.4x, which is very conservative (89% below the sector average of 3.1x). The company holds a net cash position — cash of $38M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.54 | — | — | — | — |
| Debt / EBITDA | 0.35 | 0.35 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | -3.14 | -1.89 | -2.54 | -1.33 | -0.47 |
| Net Debt / EBITDA | -1.07 | -1.07 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -56.61 | — | — | -1.05 | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -35.28 | -19.17 |
Net cash position: cash ($38M) exceeds total debt ($9M)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.25x means CytomX Therapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.55x to 1.25x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | 1.25 | 1.17 | 1.55 | 3.98 | 4.76 | 3.54 | 4.55 | 6.36 | 5.26 | 12.06 |
| Quick Ratio | 1.25 | 1.25 | 1.17 | 1.55 | 3.98 | 4.76 | 3.54 | 4.55 | 6.36 | 5.26 | 12.06 |
| Cash Ratio | 1.17 | 1.17 | 1.12 | 1.27 | 3.92 | 4.64 | 3.46 | 4.45 | 6.12 | 5.09 | 11.86 |
| Asset Turnover | — | 1.15 | 0.50 | 0.20 | 0.11 | 0.19 | 0.17 | 0.13 | 0.18 | 0.08 | 0.04 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 8.20 | 12.38 | 247.07 | 7.73 | 4.26 | 0.08 | 0.59 | 51.67 | 56.12 | 35.21 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CytomX Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 7.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 0.9% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.1% | 36.9% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 1.0% | — | — | 21.5% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% |
| Shares Outstanding | — | $85M | $74M | $66M | $64M | $46M | $45M | $42M | $37M | $36M | $35M |
Compare CTMX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CTMXYou | $430M | 14.1 | 15.0 | — | 100.0% | 18.1% | — | — | 0.4 |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 12 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CTMX stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonCytomX Therapeutics, Inc.'s current P/E ratio is 14.1x. The historical average is 2.7x. This places it at the 100th percentile of its historical range.
CytomX Therapeutics, Inc.'s current EV/EBITDA is 15.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 2.2x.
Based on historical data, CytomX Therapeutics, Inc. is trading at a P/E of 14.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CytomX Therapeutics, Inc. has 100.0% gross margin and 18.1% operating margin. Operating margin between 10-20% is typical for established companies.
CytomX Therapeutics, Inc.'s Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.